ACHIEVE LIFE SCIENCES INC. - COMMON SHARES

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

12 Jan 2026 08:47:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

08 Dec 2025 16:10:53 By Nasdaq GlobeNewswire

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

06 Nov 2025 07:00:02 By Nasdaq GlobeNewswire

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

03 Nov 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

29 Oct 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

20 Oct 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

17 Oct 2025 07:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

02 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

22 Sep 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

18 Sep 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

11 Sep 2025 17:01:44 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

03 Sep 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

02 Sep 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

07 Aug 2025 07:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

29 Jul 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

24 Jul 2025 08:30:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities

30 Jun 2025 19:52:40 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

26 Jun 2025 23:43:33 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Proposed Underwritten Public Offering

26 Jun 2025 16:03:00 By Nasdaq GlobeNewswire

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

26 Jun 2025 16:02:00 By Nasdaq GlobeNewswire